Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases

Cancer

Volumn 88, Issue 6, 2000, Pages 1393-1402

  Malone, Kathleen E ^a,b   Daling, Janet R ^a,b   Neal, Cassandra ^a   Suter, Nicola M ^a   O'Brien, Cecilia ^a   Cushing Haugen, Kara ^a   Jonasdottir, Thora J ^a   Thompson, Jennifer D ^a   Ostrander, Elaine A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

BRCA1; BRCA2; Breast carcinoma; Population

Indexed keywords

ADULT; ARTICLE; BREAST CARCINOMA; CANCER SCREENING; CASE CONTROL STUDY; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MUTATION RATE; ONCOGENE; POPULATION RESEARCH; PRIORITY JOURNAL;

ADULT; AGE FACTORS; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; CODON; CONFIDENCE INTERVALS; FEMALE; FRAMESHIFT MUTATION; GENES, BRCA1; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; POPULATION SURVEILLANCE; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 0034653903     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P     Document Type: Article

References (35)

1. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-9.
2. Narod SA, Feunteun J, Lynch HT, Watson P, Conway T, Lynch J, et al. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 1991;338:82-3.
3. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265: 2088-90.
4. Castilla LH, Couch FJ, Erdos MR, Hoskins KF, Calzone K, Garber JE, et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet 1994; 8:387-91.
5. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994;8:399-404.
6. Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, et al. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 1995;57:1284-97.
7. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, ei al. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet 1996;58:271-80.
8. Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, et al. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet 1997;60:486-95.
9. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198-200.
10. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2 [editorial]. Am J Hum Genet 1997;60:1013-20.
11. Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA. BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 1998;279:922-9.
12. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998;279:915-21.
13. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14:188-90.
14. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
15. Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998;352:1337-9.
16. Brinton LA, Daling JR, Liff JM, Schoenberg JB, Malone KE, Stanford J, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 1995;87:827-35.
17. Daling JR, Malone KE, Voigt LF, White E, Weiss NS. Risk of breast cancer among young women: relationship to induced abortion. J Natl Cancer Inst 1994;86:1584-92.
18. Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G, et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997;60: 313-9.
19. Kirkpatrick H, Waber P, Hoa-Thai T, Barnes R, Osborne-Lawrence S, Truelson J, et al. Infrequency of BRCA2 alterations in head and neck squamous cell carcinoma. Oncogene 1997;14:2189-93.
20. Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 1996;334: 137-42.
21. Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi D, et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogens 1998;16:1713-21.
22. Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS, et al. A polymorphic stop codon in BRCA2 [letter]. Nat Genet 1996;14:253-4.
23. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1996;336:1409-15.
24. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
25. Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995;56: 254-64.
26. Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J, et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 1997;60:1031-40.
27. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996;12:333-7.
28. Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997;278: 1242-50.
29. Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ishioka C, Kanamaru R, et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 1997;336:1416-21.
30. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48:232-42.
31. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57:1457-62.
32. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496-504.
33. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-89.
34. Jordanova A, Kalaydjieva L, Savov A, Claustres M, Schwarz M, Estivill X, et al. SSCP analysis: a blind sensitivity trial. Human Mutat 1997;10:65-70.
35. Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW, Stone EM. The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. Genomics 1993;16:325-32.